ProCE Banner Activity

GIM4 LEAD: Phase III Trial of Extended Adjuvant Therapy With Letrozole After Sequential Endocrine Therapy in Patients With HR+ Early Breast Cancer

Slideset Download
Conference Coverage
Extended adjuvant endocrine therapy with an additional 5 years of letrozole after tamoxifen prolonged DFS compared with standard-duration sequential endocrine therapy with letrozole in patients with HR-positive early breast cancer.

Released: June 05, 2019

Expiration: June 03, 2020

No longer available for credit.

Share

Provided by

Provided by the USF Health
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Astellas Seattle Genetics

Bayer Healthcare Pharma

Blueprint Medicines

Celgene

Novartis Pharmaceuticals Corporation

Puma Biotechnology, Inc.

Taiho Oncology Inc

Tesaro